Drug Database · Clinicians

Vinorelbine

Brands (6) Vinobin, Navelbine, Prorelbine…Show all

Antineoplastic agent (vinca Alkaloid/Analogue); Antineoplastic agent (vinca alkaloids and analogues); and others PH FDA category

Rx · Prescription drug12 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 10a70995-e04d-4044-b1dc-c9aa27460397, version date August 16, 2024 (Vinorelbine · Sagent Pharmaceuticals). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC Vinorelbine…
  • As a single agent for first-line treatment of patients with metastatic NSCLC
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Vinorelbine Injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC Vinorelbine Injection is a vinca alkaloid indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (1) As a single agent for first-line treatment of patients with metastatic NSCLC (1)

Contraindications

4 CONTRAINDICATIONS None None

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • In combination with cisplatin: 25 to 30 mg/m 2 as an intravenous injection or infusion once weekly (2.1)
  • Single agent: 30 mg/m 2 as intravenously once a week (2.1)
  • Adjust dose in patients with decreased neutrophil counts or elevated serum total bilirubin (2.2)
2.1 Recommended Dosage

2.1 Recommended Dosage In Combination with Cisplatin 100 mg/m 2 The recommended dosage of Vinorelbine Injection is 25 mg/m 2 administered as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle in combination with cisplatin 100 mg/m 2 on Day 1 only of each 28-day cycle. In Combination with Cisplatin 120 mg/m 2 The recommended dosage of Vinorelbine Injection is 30 mg/m 2 administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m 2 on Days 1 and 29, then every 6 weeks.

Single Agent The recommended dosage of Vinorelbine Injection is 30 mg/m 2 administered intravenously over 6 to 10 minutes once a week.

2.2 Dosage Modifications Myelosuppression

2.2 Dosage Modifications Myelosuppression Hold or decrease the dose of Vinorelbine Injection in patients with decreased neutrophil counts according to the following schema [see Warnings and Precautions (5.1)]: Neutrophils on Day of Treatment (cells/mm 3) Percentage of Starting Dose of Vinorelbine Injection ≥ 1,500 100% 1,000 to 1,499 50% < 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week.

If three consecutive weekly doses are held because neutrophil count is < 1,000 cells/mm 3, discontinue Vinorelbine Injection Note: For patients who experience fever and/or sepsis while neutrophil count is < 1,500 cells/mm 3 or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of Vinorelbine Injection should be: > 1,500 75% 1,000 to 1,499 37.5% < 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week.

Hepatic Impairment/Toxicity Reduce Vinorelbine Injection dose in patients with elevated serum total bilirubin concentration according to the following schema [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)]: Serum Total Bilirubin Concentration (mg/dl) Percentage of Starting Dose of Vinorelbine Injection ≤ 2.0 100% 2.1 to 3.0 50% > 3.0 25% Concurrent Myelosuppression and Hepatic Impairment/Toxicity In patients with both myelosuppression and hepatic impairment/toxicity, administer the lower of the doses based on the corresponding starting dose of Vinorelbine Injection determined from the above schemas. Neurologic Toxicity Discontinue Vinorelbine Injection for Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher peripheral neuropathy or autonomic neuropathy causing constipation [see Warnings and Precautions (5.5)].

2.3 Preparation and Administration

2.3 Preparation and Administration Preparation Dilute Vinorelbine Injection in an intravenous bag to a concentration between 0.5 mg/mL and 2 mg/mL. Use one of the following recommended solutions for dilution: 5% Dextrose Injection, USP 0.9% Sodium Chloride Injection, USP 0.45% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP Ringer's Injection, USP Lactated Ringer's Injection, USP Stability and Storage Conditions of Diluted Solutions Diluted Vinorelbine Injection may be used for up to 24 hours under normal room light when stored in polyvinyl chloride bags at 5° to 30°C (41° to 86°F).

Administration Administer diluted Vinorelbine Injection over 6 to 10 minutes into the side port of a free-flowing intravenous line followed by flushing with at least 75 to 125 mL of one of the solutions. Vinorelbine Injection must only be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any Vinorelbine Injection is injected.

Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If particulate matter is seen, Vinorelbine Injection should not be administered. Management of Suspected Extravasation If Vinorelbine Injection leakage into surrounding tissue occurs or is suspected, immediately stop administration of Vinorelbine Injection and initiate appropriate management measures in accordance with institutional policies [see Warnings and Precautions (5.4)].

2.4 Procedures for Proper Handling and Disposal

2.4 Procedures for Proper Handling and Disposal Vinorelbine Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures 1. Exercise caution in handling and preparing the solution of Vinorelbine Injection. The use of gloves is recommended. If the solution of Vinorelbine Injection contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water.

Avoid contamination of the eye with Vinorelbine Injection. If exposure occurs, flush the eyes with water immediately and thoroughly. Discard unused portion.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment The influence of hepatic impairment on the pharmacokinetics of vinorelbine has not been evaluated, but the liver plays an important role in the metabolism of vinorelbine. Elevated AST occurs in >60% of the patients receiving vinorelbine as a single agent (6% Grade 3-4). Therefore, exercise caution in patients with hepatic impairment. Reduce the dose of vinorelbine for patients with elevated serum total bilirubin concentrations [see Dosage and Administration (2.2) and Warnings and Precautions (5.2)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of vinorelbine in pediatric patients have not been established. Results from a single-arm study of vinorelbine administered at the dose of 33.75 mg/m 2 (for 35 patients) or at the dose of 30 mg/m 2 (for 11 patients) every week for 6 weeks followed by 2 weeks of rest were evaluated (courses of 8 weeks).

Forty-six patients age 1 to 25 (median 11 years) with recurrent solid malignant tumors, including rhabdomyosarcoma or undifferentiated sarcoma (N=21 patients), neuroblastoma (N= 4 patients) and central nervous system (CNS) tumors (N=21 patients), were enrolled. The most significant grade 3 or 4 hematological adverse reactions were neutropenia (70%) and anemia (33%).

The most significant grade 3 or 4 non-hematological adverse reactions were motor (15%) or cranial (13%) neuropathy, hypoxia (13%) and dyspnea (11%). Objective tumor response was observed in 2 out of 21 patients with rhabdomyosarcoma or undifferentiated sarcoma. No objective tumor response was observed in patients with CNS tumors (N=21) or neuroblastoma (N=4).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 769 number of patients who received vinorelbine as a single agent and in combination with cisplatin in studies 1, 2 and 3, 247 patients were 65 years of age or older. No overall differences in safety, efficacy and pharmacokinetic parameters were observed between these patients and younger patients [see Clinical Pharmacology (12.3)].

Administration

2.3 Preparation and Administration Preparation Dilute Vinorelbine Injection in an intravenous bag to a concentration between 0.5 mg/mL and 2 mg/mL. Use one of the following recommended solutions for dilution: 5% Dextrose Injection, USP 0.9% Sodium Chloride Injection, USP 0.45% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP Ringer's Injection, USP Lactated Ringer's Injection, USP Stability and Storage Conditions of Diluted Solutions Diluted Vinorelbine Injection may be used for up to 24 hours under normal room light when stored in polyvinyl chloride bags at 5° to 30°C (41° to 86°F). Administration Administer diluted Vinorelbine Injection over 6 to 10 minutes into the side port of a free-flowing intravenous line followed by flushing with at least 75 to 125 mL of one of the solutions. Vinorelbine Injection must only be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any Vinorelbine Injection is injected. Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If particulate matter is seen, Vinorelbine Injection should not be administered. Management of Suspected Extravasation If Vinorelbine Injection leakage into surrounding tissue occurs or is suspected, immediately stop administration of Vinorelbine Injection and initiate appropriate management measures in accordance with institutional policies [see Warnings and Precautions ( 5.4 )].

US FDA label

Dosage forms

Philippines

  • Softgel capsule: 20 mg, 30 mg, 80 mg
  • Soft-gelatin capsule: 20 mg, 30 mg
  • ) solution for injection: 10 mg/mL (50 mg/5 mL
  • Solution for i.v. infusion: 10 mg/mL

Registered products in the Philippines

12 products registered with the Food and Drug Administration (FDA) Philippines list Vinorelbine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products12
Philippine FDA-registered products for Vinorelbine
Package insert
LealrelbinVinorelbine (as tartrate)
30 mg Softgel CapsulePVC/PVDC-Alu Blister with Child-Resistant Safety Paper Layer x 1 (Box of 1's)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Workshop HS108)China
Lealmeds Pharmaceutical Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-15800-01
Sep 18, 2029
NavelbineVinorelbine (as tartrate)
20 mg Soft-Gelatin CapsulePVC/PVDC-Alu Blister Pack x 1 's (Box of 1)
RxVAT-exempt
Fareva PauFrance
Zuellig Pharma CorporationImporter: OEP Philippines, Inc.Trader: Pierre Fabre Medicament
DR-XY44861
Oct 7, 2030
NavelbineVinorelbine (as tartrate)
30 mg Soft-Gelatin CapsulePVC/PVDC-Alu Blister Pack x 1 's Box of 1's
RxVAT-exempt
Fareva PauFrance
Zuellig Pharma CorporationImporter: OEP Philippines, Inc.Trader: Pierre Fabre Medicament
DR-XY44860
Oct 7, 2030
ProrelbineVinorelbine (as Tartrate)
10 mg/ mL (50mg/5mL) Solution For Injection (IV)2 ml Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Sky-Blue Aluminum Flip-Off Seal Cap x 1mL (Net content) (Box of l’s); 6 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Olive Drab Aluminum Flip-Off Seal Cap x 5mL (Net content) (Box of l’s)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Co., Ltd.China
Ambicare Pharmaceuticals, Inc.
DRP-12331
Jul 19, 2027
ProrelbineVinorelbine (as tartrate)
30 mg Softgel CapsulePVC/PVDC-Alu Blister with Child-Resistant Safety Paper Layer x 1 (Box of 1's)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Workshop HS108)China
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-15800
Sep 18, 2029
Verlene-20Vinorelbine
20 mg Softgel CapsuleClear PVC/PVDC-Alu Blister Pack x 1's (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
One Dexcel Pharma Inc.
DRP-16478
Mar 25, 2030
VinobinVinorelbine (as tartrate)
20 mg Softgel CapsulePVC/PVDC/Alu/PET/Paper Child-Resistant Blister Pack x l's (Box of l’s)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd (Nantou Plant)Taiwan
Metro Drug, Inc.Trader: Alvogen Emerging Markets Holdings Limited
DR-XY48175
Jul 8, 2027
VinobinVinorelbine (as tartrate)
20 mg Softgel CapsulePVC/PVDC/Alu/PET/Paper Child-Resistant Blister Pack x 1's (Box of 1's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Importer: Lotus Healthcare Philippines Corp.Trader: Lotus Pharmaceutical Co., Ltd.,Taiwan
DRP-15256
Jul 8, 2027
VinobinVinorelbine (as tartrate)
30 mg Softgel capsulePVC/PVDC-Al/PET/Paper Child Resistant Blister Pack x l's (Box of 1's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.Trader: Alvogen Emerging Markets Holdings Limited
DR-XY47738
Mar 10, 2027
VinobinVinorelbine (as tartrate)
30 mg Softgel CapsulePVC/PVDC-Al/PET/Paper Child Resistant Blister Pack x 1's (Box of 1's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Importer: Lotus Healthcare Philippines Corp.Trader: Lotus Pharmaceutical Co., Ltd.,Taiwan
DRP-15258
Mar 10, 2027
VinobinVinorelbine (as tartrate)
80 mg Softgel CapsulePVC/PVDC-Alu blister (with a child-resistant safety paper layer) x 1's and 4's (box of 1's and 4's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Lotus Healthcare Philippines Corporation
DR-XY49602
Jan 5, 2031
VinotelVinorelbine (as tartrate)
10 mg/mL Solution For I.V. Infusion5 mL-Capacity USP Type I Glass Vial with Fluorotec rubber plug stopper and Aluminum Flip-off Seal x 1 mL (net content) (Box of 1's); 5 mL-Capacity USP Type I Glass Vial with Fluorotec rubber stopper and Aluminum Flip-off Seal x 5 mL (net content) (Box of 1's)
RxVAT-exempt
Fresenius Kabi Oncology Limited.India
Importer: Fresenius Kabi Philippines, Inc.
DR-XY48629
Feb 15, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Vinorelbine Injection, USP: 1 mL (10 mg per 1 mL) and 5 mL (50 mg per 5 mL) clear colorless to pale yellow solution in single-dose vial. Vinorelbine Injection: 10 mg per 1 mL and 50 mg per 5 mL in single-dose vial (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment (5.2)
  • Severe constipation and bowel obstruction, including necrosis and perforation, occur. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus (5.3)
  • Extravasation can result in severe tissue injury, local tissue necrosis and/or thrombophlebitis. Immediately stop vinorelbine and institute recommended management procedures (5.4)
  • Neurologic Toxicity: Severe sensory and motor neuropathies occur. Monitor patients for new or worsening signs and symptoms of neuropathy. Discontinue for Grade 2 or greater neuropathy (5.5)
  • Pulmonary toxicity and respiratory failure occur. Interrupt vinorelbine in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity. Permanently discontinue for confirmed interstitial pneumonitis or ARDS (5.6)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus and to use effective contraception (5.7, 8.1, 8.3)
5.1 Myelosuppression

5.1 Myelosuppression Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin [see Adverse Reactions (6.1, 6.2)]. Neutropenia is the major dose-limiting toxicity with vinorelbine. Grade 3-4 neutropenia occurred in 53% of patients treated with vinorelbine at 30 mg/m 2 per week.

Dose adjustment due to myelosuppression occurred in 51% of patients (Study 2). In clinical trials with vinorelbine administered at 30 mg/m 2 per week, neutropenia resulted in hospitalizations for pyrexia and/or sepsis in 8% of patients. Death due to sepsis occurred in 1% of patients. Neutropenia nadirs occur between 7 and 10 days after dosing with neutropenia count recovery usually occurring within the following 7 to 14 days.

Monitor complete blood counts prior to each dose of vinorelbine. Do not administer vinorelbine to patients with neutrophil counts <1,000 cells/mm 3. Adjustments in the dosage of vinorelbine should be based on neutrophil counts obtained on the day of treatment [see Dosage and Administration (2.2)].

5.2 Hepatic Toxicity

5.2 Hepatic Toxicity Drug-induced liver injury manifest by elevated aspartate aminotransferase (AST) and bilirubin occur in patients receiving vinorelbine as a single agent and in combination with cytotoxic agents. Assess hepatic function prior to initiation of vinorelbine and periodically during treatment. Reduce the dose of vinorelbine for patients who develop elevations in total bilirubin ≥ 2 times upper limit of normal [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

5.3 Severe Constipation and Bowel Obstruction

5.3 Severe Constipation and Bowel Obstruction Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.

5.4 Extravasation and Tissue Injury

5.4 Extravasation and Tissue Injury Extravasation of vinorelbine can result in severe irritation, local tissue necrosis and/or thrombophlebitis. If signs or symptoms of extravasation occur, immediately stop administration of vinorelbine and institute recommended management procedures [see Dosage and Administration (2.2) and Adverse Reactions (6.1)].

5.5 Neurologic Toxicity

5.5 Neurologic Toxicity Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine. Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine. Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy [see Dosage and Administration (2.2) and Adverse Reactions (6.1)].

5.6 Pulmonary Toxicity and Respiratory Failure

5.6 Pulmonary Toxicity and Respiratory Failure Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, acute respiratory distress syndrome (ARDS) occur in patients receiving vinorelbine. Interstitial pneumonitis and ARDS included fatalities. The mean time to onset of interstitial pneumonitis and ARDS after vinorelbine administration was one week (range 3 to 8 days) [see Adverse Reactions (6.1)].

Interrupt vinorelbine in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity. Permanently discontinue vinorelbine for confirmed interstitial pneumonitis or ARDS.

5.7 Embryo-Fetal Toxicity

5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with vinorelbine and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with vinorelbine and for 3 months after the final dose [see Use in Specific Populations (8.1, 8.3)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions (7.1) 7.1 CYP3A Inhibitors Exercise caution in patients concurrently taking drugs known to inhibit CYP3A. Concurrent administration of vinorelbine with a CYP3A inhibitor may cause an earlier onset and/or an increased severity of adverse reactions.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

The metabolism of vinorelbine is mediated by hepatic CYP3A.

7 DRUG INTERACTIONS Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions ( 7.1 ) 7.1 CYP3A Inhibitors Exercise caution in patients concurrently taking drugs known to inhibit CYP3A.

Concurrent administration of vinorelbine with a CYP3A inhibitor may cause an earlier onset and/or an increased severity of adverse reactions.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions (5.1)] Hepatic Toxicity [see Warnings and Precautions (5.2)] Severe Constipation and Bowel Obstruction [see Warnings and Precautions (5.3)] Extravasation and Tissue Injury [see Warnings and Precautions (5.4)] Neurologic Toxicity [see Warnings and Precautions (5.5)] Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.6)] Most common adverse reactions (incidence ≥ 20%) are leukopenia, neutropenia, anemia, increased aspartate aminotransferase, nausea, vomiting, constipation, asthenia, injection site reaction and peripheral neuropathy (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial and may not reflect the rates actually observed in clinical practice. Single Agent The data below reflect exposure to vinorelbine as a single agent administered at a dose of 30 mg/m 2 on a weekly basis to 365 patients enrolled in 3 controlled studies for metastatic NSCLC and advanced breast cancer.

The population included 143 patients with previously untreated metastatic NSCLC (Study 3) who received a median of 8 doses of vinorelbine. The patients were aged 32 to 79 (median 61 years), 71% were male, 91% White, 48% had adenocarcinoma histology. The data also reflect exposure to vinorelbine in 222 patients with previously treated advanced breast cancer who received a median of 10 doses of vinorelbine.

Vinorelbine is not indicated for the treatment of breast cancer. Selected adverse reactions reported in these studies are provided in Tables 1 and 2. The most common adverse reactions (≥ 20%) of single agent vinorelbine were leukopenia, neutropenia, anemia, increased aspartate aminotransferase (AST), nausea, vomiting, constipation, asthenia, injection site reaction and peripheral neuropathy.

The most common (≥ 5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, anemia, increased total bilirubin, increased AST, injection site reaction and asthenia. Approximately 49% of patients with NSCLC who were treated with vinorelbine experienced at least one dose reduction due to an adverse reaction. Thirteen percent of patients discontinued vinorelbine due to adverse reactions.

The most frequent adverse reactions leading to vinorelbine discontinuation were asthenia, dyspnea, nausea, constipation, anorexia, myasthenia and fever. Table 1: Hematologic Adverse Reactions Experienced in > 5% of Patients Receiving Vinorelbine *†: * Grade based on modified criteria from the National Cancer Institute version 1. † Patients with NSCLC had not received prior chemotherapy.

The majority of the remaining patients had received prior chemotherapy. All Patients (N=365) (%) NSCLC (N=143) (%) Laboratory Hematologic Neutropenia < 2,000 cells/mm 3 90 80 < 500 cells/mm 3 36 29 Leukopenia < 4,000 cells/mm 3 92 81 < 1,000 cells/mm 3 15 12 Thrombocytopenia < 100,000 cells/mm 3 5 4 Anemia < 11 g/dl 83 77 < 8 g/dl 9 1 Hospitalizations due to neutropenic complications 9 8 Table 2: Non-hematologic Adverse Reactions Experienced in ≥ 5% of Patients Receiving Vinorelbine *†: * Grade based on modified criteria from the National Cancer Institute version 1. † Patients with NSCLC had not received prior chemotherapy.

The majority of the remaining patients had received prior chemotherapy. ‡ Incidence of paresthesia plus hypesthesia. All Grades Grade 3-4 All Patients (%) NSCLC (%) All Patients (%) NSCLC (%) Laboratory Hepatic AST increased (N=346) 67 54 6 3 Bilirubin increased (N=351) 13 9 7 5 Clinical Nausea 44 34 2 1 Asthenia 36 27 7 5 Constipation 35 29 3 2 Injection site reaction 28 38 2 5 Injection site pain 16 13 2 1 Neuropathy peripheral ‡ 25 20 <2 1 Vomiting 20 15 2 1 Diarrhea 17 13 1 1 Alopecia 12 12 ≤1 1 Phlebitis 7 10 <1 1 Dyspnea 7 3 3 2 Myelosuppression: In clinical trials, Grade 3-4 neutropenia, anemia and thrombocytopenia occurred in 69%, 9% and 1%, respectively of patients receiving single agent vinorelbine.

Neutropenia is the major dose-limiting toxicity. Neurotoxicity: Neurotoxicity was most commonly manifested as constipation, paresthesia, hyperesthesia and hyporeflexia. Grade 3 and 4 neuropathy was observed in 1% of the patients receiving single agent vinorelbine. Injection Site Reactions: Injection site reactions, including erythema, pain at injection site and vein discoloration, occurred in approximately one third of patients; 5% were severe.

Phlebitis (chemical phlebitis) along the vein proximal to the site of injection was reported in 10% of patients. Cardiovascular Toxicity: Chest pain occurred in 5% of patients; myocardial infarction occurred in ˂0.1% of patients. Pulmonary Toxicity and Respiratory Failure: Dyspnea (shortness of breath) was reported in 3% of patients; it was severe in 2%.

Interstitial pulmonary changes were documented. Other: Hemorrhagic cystitis and the syndrome of inappropriate ADH secretion were each reported in <1% of patients. In Combination with Cisplatin Table 3 presents the incidence of selected adverse reactions, occurring in ≥10% of vinorelbine treated patients reported in a randomized trial comparing the combination of vinorelbine 25 mg/m 2 administered every week of each 28-day cycle and cisplatin 100 mg/m 2 administered on day 1 of each 28-day cycle versus cisplatin alone at the same dose and schedule in patients with previously untreated NSCLC (Study 1).

Patients randomized to vinorelbine plus cisplatin received a median of 3 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. The incidence of Grade 3 and 4 neutropenia was significantly higher in the vinorelbine plus cisplatin arm (82%) compared to the cisplatin alone arm (5%).

Thirty-five percent of the eligible patients in the combination arm required treatment discontinuation due to an adverse reaction compared to 19% in the cisplatin alone arm. Four patients in the vinorelbine plus cisplatin arm died of neutropenic sepsis. Seven additional deaths were reported in the combination arm: 2 from cardiac ischemia, 1 cerebrovascular accident, 1 multisystem failure due to an overdose of vinorelbine and 3 from febrile neutropenia.

Table 3: Adverse Reactions Experienced by ≥ 10% of Patients on Vinorelbine plus Cisplatin versus Single Agent Cisplatin * * Graded according to the standard SWOG criteria version 1. † Categorical toxicity grade not specified Vinorelbine 25mg/m 2 plus Cisplatin 100 mg/m 2 (N=212) Cisplatin 100 mg/m 2 (N=210) All Grades (%) Grades 3 - 4 (%) All Grades (%) Grades 3-4 (%) Laboratory Hematologic Neutropenia 89 82 26 5 Anemia 89 24 72 <8 Leukopenia 88 58 31 <1 Thrombocytopenia 29 5 21 <2 Febrile neutropenia † N/A 11 N/A 0 Renal Blood creatinine increased 37 4 28 <5 Clinical Malaise/Fatigue/Lethargy 67 12 49 8 Vomiting 60 13 60 14 Nausea 58 14 57 12 Decreased appetite 46 0 37 0 Constipation 35 3 16 1 Alopecia 34 0 14 0 Weight decreased 34 1 21 <1 Fever without infection 20 2 4 0 Hearing impaired 18 4 18 <4 Injection site reaction 17 <1 1 0 Diarrhea 17 <3 11 <2 Paraesthesia 17 <1 10 <1 Taste alterations 17 0 15 0 Peripheral numbness 11 2 7 <1 Myalgia/Arthralgia 12 <1 3 <1 Phlebitis/Thrombosis/Embolism 10 3 <1 <1 Weakness 12 <3 7 2 Infection 11 <6 <1 <1 Respiratory tract infection 10 <5 3 3 Table 4 presents the incidence of selected adverse reactions, occurring in ≥10% of vinorelbine treated patients reported in a randomized trial of vinorelbine plus cisplatin, vindesine plus cisplatin and vinorelbine as a single agent in patients with stage III or IV NSCLC who had not received prior chemotherapy. A total of 604 patients received either vinorelbine 30 mg/m 2 every week plus cisplatin 120 mg/m 2 on Day 1 and Day 29, then every 6 weeks thereafter (N=207), vindesine 3 mg/m 2 for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m 2 on Days 1 and Day 29, then every 6 weeks thereafter (N=193) or vinorelbine 30mg/m 2 every week (N=204).

Patients randomized to vinorelbine plus cisplatin received a median of 15 weeks of treatment, vindesine plus cisplatin 12 weeks and vinorelbine received 13 weeks. Grade 3 and 4 neutropenia was significantly greater in the vinorelbine plus cisplatin arm (78%) compared to vindesine plus cisplatin (48%) and vinorelbine as a single agent (53%).

Neurotoxicity, including peripheral neuropathy and constipation, was reported in 44% (Grade 3-4, 7%) of the patients receiving vinorelbine plus cisplatin, 58% (Grade 3-4, 17%) of the patients receiving vindesine and cisplatin and 44% (Grade 3-4, 8.5%) of the patients receiving vinorelbine as a single agent. Study discontinuation due to an adverse reaction was required in 27, 22 and 10% of the patients randomized to vinorelbine plus cisplatin, vindesine plus cisplatin and cisplatin alone arms, respectively.

Table 4: Adverse Reactions Experienced by ≥ 10 % of Patients from a Comparative Trial of Vinorelbine Plus Cisplatin versus Vindesine Plus Cisplatin versus Single Agent Vinorelbine * * Grade based on criteria from the World Health Organization (WHO). † N=194 to 207; all patients receiving vinorelbine/cisplatin with laboratory and non-laboratory data. ‡ N=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data. § N=165 to 201; all patients receiving vinorelbine with laboratory and non-laboratory data. ¦ Categorical toxicity grade not specified. ¶ Neurotoxicity includes peripheral neuropathy and constipation. Vinorelbine/Cisplatin † Vindesine/Cisplatin ‡ Vinorelbine § All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Laboratory Hematologic Neutropenia 95 78 79 48 85 53 Leukopenia 94 57 82 27 83 32 Thrombocytopenia 15 4 10 3.5 3 0 Renal Blood creatinine increased ¦ 46 N/A 37 N/A 13 N/A Clinical Nausea/Vomiting 74 30 72 25 31 2 Alopecia 51 7.5 56 14 30 2 Neurotoxicity ¶ 44 7 58 17 44 8.5 Diarrhea 25 1.5 24 1 12 0.5 Injection site reaction 17 2.5 7 0 22 2 Ototoxicity 10 2 14 1 1 0

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of vinorelbine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infections: pneumonia Immune system disorders: anaphylactic reaction, pruritus, urticaria, angioedema Nervous system disorders: loss of deep tendon reflexes, muscular weakness, gait disturbance, headache Ear and labyrinth disorders: vestibular disorder, hearing impaired Cardiac disorders: tachycardia Respiratory disorders: pulmonary edema Vascular disorders: pulmonary embolism, deep vein thrombosis, hypertension, hypotension, flushing, vasodilatation Gastrointestinal disorders: mucosal inflammation, dysphagia, pancreatitis Skin disorders: generalized cutaneous reactions (rash), palmar-plantar erythrodysesthesia syndrome Musculoskeletal and connective tissue disorders: jaw pain, myalgia, arthralgia General disorders and administration site conditions: injection site rash, urticaria, blistering, sloughing of skin Injury, poisoning and procedural complications: radiation recall phenomenon, dermatitis, esophagitis Laboratory abnormalities: electrolyte imbalance including hyponatremia Other: tumor pain, back pain, abdominal pain

Adverse reaction frequency tables (US label) US FDA label
Table 1: Hematologic Adverse Reactions Experienced in > 5% of Patients Receiving Vinorelbine*†:
*Grade based on modified criteria from the National Cancer Institute version 1.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.
All Patients (N=365) (%)NSCLC (N=143) (%)
Laboratory
Hematologic
Neutropenia < 2,000 cells/mm390 80
< 500 cells/mm336 29
Leukopenia < 4,000 cells/mm392 81
< 1,000 cells/mm315 12
Thrombocytopenia < 100,000 cells/mm35 4
Anemia < 11 g/dl 83 77
< 8 g/dl 9 1
Hospitalizations due to neutropenic complications 9 8
Table 2: Non-hematologic Adverse Reactions Experienced in ≥ 5% of Patients Receiving Vinorelbine*†:
*Grade based on modified criteria from the National Cancer Institute version 1.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.
‡ Incidence of paresthesia plus hypesthesia.
All GradesGrade 3-4
All Patients (%)NSCLC (%)All Patients (%)NSCLC (%)
Laboratory
Hepatic
AST increased (N=346) 67 54 6 3
Bilirubin increased (N=351) 13 9 7 5
Clinical
Nausea 44 34 2 1
Asthenia 36 27 7 5
Constipation 35 29 3 2
Injection site reaction 28 38 2 5
Injection site pain 16 13 2 1
Neuropathy peripheral‡25 20 <2 1
Vomiting 20 15 2 1
Diarrhea 17 13 1 1
Alopecia 12 12 ≤1 1
Phlebitis 7 10 <1 1
Dyspnea 7 3 3 2
Table 3: Adverse Reactions Experienced by ≥ 10% of Patients on Vinorelbine plus Cisplatin versus Single Agent Cisplatin*
*Graded according to the standard SWOG criteria version 1.
†Categorical toxicity grade not specified
Vinorelbine 25mg/m2 plus Cisplatin 100 mg/m2 (N=212)Cisplatin 100 mg/m2 (N=210)
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Laboratory
Hematologic
Neutropenia 89 82 26 5
Anemia 89 24 72 <8
Leukopenia 88 58 31 <1
Thrombocytopenia 29 5 21 <2
Febrile neutropenia†N/A 11 N/A 0
Renal
Blood creatinine increased 37 4 28 <5
Clinical
Malaise/Fatigue/Lethargy 67 12 49 8
Vomiting 60 13 60 14
Nausea 58 14 57 12
Decreased appetite 46 0 37 0
Constipation 35 3 16 1
Alopecia 34 0 14 0
Weight decreased 34 1 21 <1
Fever without infection 20 2 4 0
Hearing impaired 18 4 18 <4
Injection site reaction 17 <1 1 0
Diarrhea 17 <3 11 <2
Paraesthesia 17 <1 10 <1
Taste alterations 17 0 15 0
Peripheral numbness 11 2 7 <1
Myalgia/Arthralgia 12 <1 3 <1
Phlebitis/Thrombosis/Embolism 10 3 <1 <1
Weakness 12 <3 7 2
Infection 11 <6 <1 <1
Respiratory tract infection 10 <5 3 3
Table 4: Adverse Reactions Experienced by ≥ 10 % of Patients from a Comparative Trial of Vinorelbine Plus Cisplatin versus Vindesine Plus Cisplatin versus Single Agent Vinorelbine*
* Grade based on criteria from the World Health Organization (WHO).
† N=194 to 207; all patients receiving vinorelbine/cisplatin with laboratory and non-laboratory data.
‡ N=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data.
§ N=165 to 201; all patients receiving vinorelbine with laboratory and non-laboratory data.
¦ Categorical toxicity grade not specified.
Neurotoxicity includes peripheral neuropathy and constipation.
Vinorelbine/Cisplatin†Vindesine/Cisplatin‡Vinorelbine§
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Laboratory
Hematologic
Neutropenia 95 78 79 48 85 53
Leukopenia 94 57 82 27 83 32
Thrombocytopenia 15 4 10 3.5 3 0
Renal
Blood creatinine increased¦46 N/A 37 N/A 13 N/A
Clinical
Nausea/Vomiting 74 30 72 25 31 2
Alopecia 51 7.5 56 14 30 2
Neurotoxicity44 7 58 17 44 8.5
Diarrhea 25 1.5 24 1 12 0.5
Injection site reaction 17 2.5 7 0 22 2
Ototoxicity 10 2 14 1 1 0

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], vinorelbine can cause fetal harm when administered to a pregnant woman. Available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Data Animal Data In a mouse embryo-fetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m 2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. Vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m 2 (approximately 0.18 times the recommended human dose based on body surface area) or greater.

At doses that did not cause maternal toxicity in either species, vinorelbine administration resulted in reduced fetal weight and delayed ossification.

Mechanism of action

12.1 Mechanism of Action Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine may also interfere with: 1) amino acid, cyclic AMP and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Vinorelbine inhibited mitotic microtubule formation in intact mouse embryo tectal plates at a concentration of 2 μM inducing a blockade of cells at metaphase, but produced depolymerization of axonal microtubules at a concentration 40 μM, suggesting a modest selectivity of vinorelbine for mitotic microtubules.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg.

Excretion After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively.

In a different study, 10.9% ± 0.7% of a 30 mg/m 2 intravenous dose was excreted as parent drug in urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of vinorelbine were studied in 49 patients who received doses of 30 mg/m 2 administered as 15- to 20-minute constant-rate infusions. Vinorelbine concentrations in plasma decay in a triphasic manner. Distribution Steady-state volume of distribution (V SS) values range from 25.4 to 40.1 L/kg.

Vinorelbine demonstrated high binding to human platelets and lymphocytes. The free fraction was approximately 0.11 in human plasma over a concentration range of 234 to 1169 ng/mL. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin, fluorouracil, or doxorubicin.

Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg. Metabolism Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces. Two metabolites of vinorelbine have been identified in human blood, plasma and urine; vinorelbine N-oxide and deacetylvinorelbine.

Deacetylvinorelbine has been demonstrated to be the primary metabolite of vinorelbine in humans and has been shown to possess antitumor activity similar to vinorelbine. Therapeutic doses of vinorelbine (30 mg/m 2) yield very small, if any, quantifiable levels of either metabolite in blood or urine. The metabolism of vinorelbine is mediated by hepatic CYP3A.

Excretion After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively. In a different study, 10.9% ± 0.7% of a 30 mg/m 2 intravenous dose was excreted as parent drug in urine. Specific Populations Age has no effect on the pharmacokinetics (CL, V SS and t 1/2) of vinorelbine.

Drug Interaction Studies The pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Vinorelbine · Sagent Pharmaceuticals [US FDA-approved label, version 10, August 16, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10a70995-e04d-4044-b1dc-c9aa27460397
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .